One national price list

Yakka (薬価) means "drug price." In Japanese health news it almost always refers to the official price that the Ministry of Health, Labour and Welfare (MHLW) sets for each prescription drug covered by public health insurance. The full list is the yakka kijun (薬価基準), the drug price standard. A drug has to be on it to be prescribed under insurance, and the pharmacy or hospital that dispenses it is paid at the listed price, whatever it paid the wholesaler. In April 2026 the list had 12,272 entries.

The ministry decides prices on the advice of the Central Social Insurance Medical Council, known as Chūikyō (中医協), where insurers, medical providers and neutral members sit together.

How a new drug is priced

New drugs are added to the list several times a year. If a similar drug is already listed, the new one is priced to match its daily treatment cost, with premiums for clear advantages or innovation. If there is nothing comparable, the price is built up from manufacturing and development costs plus margins. Of the 415 new active substances priced between April 2018 and August 2025, 108, about a quarter, were priced from costs.

Why prices keep falling

After listing, the price follows the market. The government surveys what wholesalers actually charge hospitals and pharmacies, and the new price is the weighted average of those prices plus consumption tax, plus a margin of 2% of the old price to keep distribution stable. Because buyers negotiate discounts, actual prices sit below the list. In the September 2025 survey the average gap was about 4.8%, so most prices are cut at each revision.

Revisions used to come every two years, together with the fees paid for medical services. Since fiscal 2021 there has also been a revision in the years between, in 2021, 2023 and 2025, and one is planned for 2027. The April 2026 revision lowered drug prices by 4.02% on average, which cut total medical spending by 0.86%.

Older brand-name drugs face extra cuts. Five years after a generic version appears, the brand is lowered step by step toward the generic price. In the 2025 survey, generics accounted for about 88.8% of volume where a generic existed.

Reading drug price stories

A yakka cut is reported two ways. For insurers and the government it is a saving. For drug makers it is a squeeze. The industry argues that low prices push companies to delay or skip launches in Japan, leaving drugs approved abroad unavailable, a problem the ministry itself calls "drug loss." The 2026 reform also noted concern that American "most favored nation" pricing, which ties US prices to those abroad, could make companies more cautious about launching new drugs in Japan.

Low prices also affect supply. Old, cheap medicines can become unprofitable to make, and makers may stop producing them. The price rules include a minimum price and a way to raise the price of products that no longer cover their costs.

The listed price is not what the patient pays. Most patients pay a share of it, usually 30%, along with the pharmacy's dispensing fees.

Sources